Cargando…
Superior antigen-specific CD4(+)T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older
BACKGROUND: The effectiveness of trivalent influenza vaccines may be reduced in older versus younger adults because of age-related immunosenescence. The use of an adjuvant in such a vaccine is one strategy that may combat immunosenescence, potentially by bolstering T-cell mediated responses. METHODS...
Autores principales: | Couch, Robert B, Bayas, José M, Caso, Covadonga, Mbawuike, Innocent Nnadi, López, Concepción Núñez, Claeys, Carine, El Idrissi, Mohamed, Hervé, Caroline, Laupèze, Béatrice, Oostvogels, Lidia, Moris, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138369/ https://www.ncbi.nlm.nih.gov/pubmed/25078387 http://dx.doi.org/10.1186/1471-2334-14-425 |
Ejemplares similares
-
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016) -
Adjuvants and adjuvanticity
por: Tizard, Ian R.
Publicado: (2021) -
Control of mucosal virus infection by influenza nucleoprotein-specific CD8(+ )cytotoxic T lymphocytes
por: Mbawuike, Innocent N, et al.
Publicado: (2007) -
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014) -
The inflammasome and alum-mediated adjuvanticity
por: Kang, Suk-Jo, et al.
Publicado: (2009)